Kyverna Therapeutics’ (KYTX) “Buy” Rating Reiterated at HC Wainwright

Kyverna Therapeutics (NASDAQ:KYTX)‘s stock had its “buy” rating reiterated by equities researchers at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $20.00 target price on the stock. HC Wainwright’s price target points to a potential upside of 95.50% from the company’s previous close.

Several other brokerages also recently issued reports on KYTX. Wall Street Zen downgraded Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Friday, March 27th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $28.67.

Kyverna Therapeutics Trading Up 5.4%

Kyverna Therapeutics stock opened at $10.23 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 7.75 and a quick ratio of 7.75. The company has a market capitalization of $619.22 million, a price-to-earnings ratio of -2.80 and a beta of 2.62. Kyverna Therapeutics has a one year low of $1.92 and a one year high of $13.67. The company’s fifty day moving average price is $8.58 and its two-hundred day moving average price is $8.10.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its earnings results on Thursday, March 26th. The company reported ($0.80) EPS for the quarter, hitting the consensus estimate of ($0.80). On average, analysts forecast that Kyverna Therapeutics will post -3.18 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kyverna Therapeutics

Hedge funds have recently made changes to their positions in the stock. Public Employees Retirement System of Ohio bought a new stake in shares of Kyverna Therapeutics in the third quarter valued at about $28,000. Qube Research & Technologies Ltd bought a new position in Kyverna Therapeutics during the second quarter worth about $43,000. Capital Advisors Inc. OK bought a new position in Kyverna Therapeutics during the third quarter worth about $60,000. Rhumbline Advisers lifted its stake in Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after purchasing an additional 5,694 shares during the period. Finally, Ameriprise Financial Inc. bought a new position in Kyverna Therapeutics during the third quarter worth about $77,000. Institutional investors own 18.08% of the company’s stock.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical?stage biotechnology company dedicated to developing engineered regulatory T?cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen?specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.